about
Systematic adjudication of myocardial infarction end-points in an international clinical trialDisagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT studyEnzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarctionGastrointestinal ulcers, role of aspirin, and clinical outcomes: pathobiology, diagnosis, and treatmentCurrent perspectives on reperfusion therapy for acute ST-segment elevation myocardial infarction: integrating pharmacologic and mechanical reperfusion strategiesExploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trialTroponin T levels in patients with acute coronary syndromes, with or without renal dysfunctionStatin use and sex-specific stroke outcomes in patients with vascular diseaseIncidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndromeA systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetesClinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous interventionEffect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data.Coordinated series of studies to evaluate characteristics and mechanisms of acute coronary syndromes in high-risk patients randomly assigned to enoxaparin or unfractionated heparin: design and rationale of the SYNERGY Library.Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: Data from the PLATO Trial.Independent data monitoring committees: preparing a path for the future.2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop CardiCause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFThe anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results.Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome.Drivers of hospitalization for patients with atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.Use of evidence-based cardiac prevention therapy among outpatients with atrial fibrillationLack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryHeparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome.Rate versus rhythm control for management of atrial fibrillation in clinical practice: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS-R trialsOutcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry.Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial.Effect of platelet inhibition with cangrelor during PCI on ischemic events.Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: study design and conduct.Results of a reevaluation of cardiovascular outcomes in the RECORD trial.Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention oFactors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global OrganizationImpact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trial.Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism TrExperience with glycoprotein IIb/IIIa antagonists in patients with acute coronary syndromes.
P50
Q24805625-B02D7072-63BB-4410-B4F0-9B0F0C31D931Q24805692-F629D2A5-D823-4DF3-A50A-6EB277932506Q24816893-39EDDE04-4AB7-4331-9B04-BE2AEF9CB14FQ27027977-6AAD2D9C-6837-4F5F-822C-43ADAC156581Q28166395-6D73DC36-2D2C-4D62-B399-57649CCD111BQ28189286-847FA7A0-FDAE-47FB-BE93-D974F26CED74Q28193293-94E9A516-EE3B-4052-BFB3-04507AE36352Q28196876-14F6DEC1-91B5-43F8-8207-4E948EAFB6D0Q28213745-DF1E254C-B402-41F1-B8CC-90BC6325A49FQ28282265-AADFB9AB-AEB4-41B8-ADF7-D02E8EAC1CD8Q29027511-36423CA0-B829-4DB4-8462-2E690092F6ECQ30665387-28FF8385-7956-4AA4-A65B-1A2C3D0E17B7Q30767089-EB46A7BE-4A7C-4937-A3AF-550D7F6C3647Q30821177-CF6DEEB1-3550-46D9-ABB0-D1CC371AD910Q30838979-517A199D-7BF8-45CA-8936-14A5AF34C7FBQ30882189-0D1B1637-961D-40F0-B2FA-0A11B59B705EQ31054764-6D1E9E22-EB9A-4FDB-BF74-DF36F19CC236Q33357490-A45C1205-C443-4C23-AF5B-BA4F5E903186Q33416754-767C31D7-4EF3-4462-92C7-6BDC1ED82CA6Q33553902-9BD90731-32AA-4802-A019-FAAE00B0BA33Q33671190-BF59657C-4684-411D-A2F7-753B00D632E1Q33680031-C6791F08-EBDE-4597-8015-D16EB4463202Q33730859-886A7495-4D11-4681-B80C-E40D5CEDBAD3Q33750461-CF8C2DC2-1C6B-449E-AE7E-CA09A6825858Q33820544-D6BE03E4-9195-4A7D-A3E2-C342C5F3A964Q33835824-6A614C36-8CE9-4241-84F9-5B80299A41EAQ34091490-0689EBBE-C0C5-4814-BDBA-640ABDCFAAFBQ34118769-6A055D7A-AB4F-4286-9DB7-C5235FD15D8EQ34231934-7B6D60B8-CEBA-453B-9130-CB839BF12278Q34297266-5D5BC032-3AD6-4766-9940-60AEBF78E6A2Q34331649-FA6DF6E4-FE1A-4398-B87B-CD6AB8DB54A7Q34331909-18B9AF6D-2D92-4774-82EC-C0057A56789BQ34360459-963AD17C-A0C9-4880-A73A-F171D6047283Q34360464-37FC02A2-6F97-401C-9BAE-030BB00DA5FAQ34388837-4075583E-C57F-4901-8786-86D046D4A0E8Q34388959-D4E33A6E-417F-494D-8677-6B11E1719E27Q34522235-C67CE958-A067-4898-9A43-E040AF4BC80AQ34633608-A09D2DB0-723F-4FC5-AF77-A24E80AE9845Q34668487-F6743810-6FFE-47AB-BA3F-F9408E75783DQ34684081-4E9ECC1A-4E76-4901-851B-BAED172A931F
P50
name
Kenneth W Mahaffey
@ast
Kenneth W Mahaffey
@en
Kenneth W Mahaffey
@nl
type
label
Kenneth W Mahaffey
@ast
Kenneth W Mahaffey
@en
Kenneth W Mahaffey
@nl
prefLabel
Kenneth W Mahaffey
@ast
Kenneth W Mahaffey
@en
Kenneth W Mahaffey
@nl